Replies to post #41 on Benitec Biopharma Ltd (BNTC)

[Wildbilly]

On attending the J.P. Morgan Biotech Conference

in San Francisco in January 2013:

We might have had a
promising technology and a major US acquisition,
but we also had a billion shares at 1.3-1.5c each.
This was quite a barrier to US investors who were
unacquainted with the quirks of the Australian
biotechnology
industry. So whilst
there was enthusiasm
and significant interest
in the potential of
ddRNAi, the capital
structure of the
company was a barrier
for many.

What would those quirks be? Lack of VC funding?